Compare CATY & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CATY | ACAD |
|---|---|---|
| Founded | 1962 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.4B | 3.8B |
| IPO Year | 1996 | 2000 |
| Metric | CATY | ACAD |
|---|---|---|
| Price | $57.28 | $21.09 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 4 | 22 |
| Target Price | ★ $52.50 | $30.55 |
| AVG Volume (30 Days) | 365.4K | ★ 1.6M |
| Earning Date | 04-22-2026 | 05-06-2026 |
| Dividend Yield | ★ 2.77% | N/A |
| EPS Growth | 14.94 | ★ 69.12 |
| EPS | ★ 1.29 | 0.02 |
| Revenue | $53,793,000.00 | ★ $726,437,000.00 |
| Revenue This Year | $20.37 | $18.80 |
| Revenue Next Year | $5.41 | $11.70 |
| P/E Ratio | ★ $44.36 | $1,066.50 |
| Revenue Growth | 2.93 | ★ 40.45 |
| 52 Week Low | $42.03 | $19.69 |
| 52 Week High | $58.00 | $28.35 |
| Indicator | CATY | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 61.27 | 44.59 |
| Support Level | $55.32 | $20.06 |
| Resistance Level | $58.00 | $22.64 |
| Average True Range (ATR) | 1.08 | 0.80 |
| MACD | -0.12 | -0.10 |
| Stochastic Oscillator | 73.13 | 29.60 |
Cathay General Bancorp is a regional bank predominantly serving the Chinese-American community. The company's policy is to reach out and actively offer services to low-to-moderate income groups in the delineated branch service areas. It predominantly provides services such as checking and deposit, lines of credits, commercial and commercial real estate loans, merchant services and payment processing, treasury management services, international banking and financing services, and other customary banking services to individuals, professionals, and small to medium-sized businesses. Through its Wealth Management unit, the company also offers investment products and services, such as stocks, bonds, mutual funds, insurance, annuities and advisory services.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.